Ассоциация медиаторов жировой ткани с развитием злокачественных новообразований на фоне метаболического синдрома

Ассоциация медиаторов жировой ткани с развитием злокачественных новообразований на фоне метаболического синдрома

Автор: Середа Е.Е., Чернышова А.Л., Мамонова Т.Ю., Какурина Г.В., Юнусова Н.В., Сиденко Е.А., Коршунов Д.А., Кондакова И.В.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 2 т.23, 2024 года.

Бесплатный доступ

Цель исследования - обобщение имеющихся данных о взаимосвязи медиаторов жировой ткани с течением злокачественных новообразований у больных с метаболическим синдромом. Материал и методы. Используя электронные ресурсы поисковых систем PubMed и eLIBRARY, проведен литературный обзор научных трудов за последние 20 лет, содержащих доказательную экспериментальную и клиническую базу по обсуждаемым вопросам. Из 400 найденных по ключевым словам публикаций в обзор включено 58 исследований.

Злокачественные новообразования, метаболический синдром, адипокины, специализированные проразрешающие медиаторы (спрм), метаболиты полиненасыщенных жирных кислот

Короткий адрес: https://sciup.org/140305900

IDR: 140305900   |   DOI: 10.21294/1814-4861-2024-23-2-101-110

Список литературы Ассоциация медиаторов жировой ткани с развитием злокачественных новообразований на фоне метаболического синдрома

  • Mili N., Paschou S.A., Goulis D.G., Dimopoulos M.A., Lambrinoudaki I., Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74(3):478-97. https://doi.org/10.1007/s12020-021-02884-x.
  • Rekomendatsii po vedeniyu bol'nykh s metabolicheskim sindromom, razrabotannye po porucheniyu Minzdrava Rossii i utverzhdennye Rossiiskim meditsinskim obshchestvom po arterial'noi gipertonii i profil'noi komissiei po kardiologii. M., 2013.
  • Chernyshova A.L., Kolomiets L.A., Yunusova N.V., Shanshashvili E.V. Osobennosti gormonal'no-energeticheskogo obmena u bol'nykh s giperplasticheskimi protsessami i rakom endometriya na fone metabolicheskogo sindroma. Sibirskii onkologicheskii zhurnal. 2015;1(1): 5-12.
  • Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Kishkina A.Y., Spirina L.V. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr. 2018; 12(5): 807-12. https://doi.org/10.1016/j.dsx.2018.04.028.
  • Conteduca V., Caffo O., Galli L., Maugeri A., Scarpi E., Maines F., Chiuri V.E., Lolli C., Kinspergher S., Schepisi G., Santoni M., Santini D., Fratino L., Burgio S.L., Salvi S., Menna C., De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 2018; 36(5). https://doi.org/10.1016/j.urolonc.2018.01.007.
  • Kokts-Porietis R.L., McNeil J., Nelson G., Courneya K.S., Cook L.S., Friedenreich C.M. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020; 158(3): 727-33. https://doi.org/10.1016/j.ygyno.2020.06.488.
  • Yang X., Li X., Dong Y., Fan Y., Cheng Y., Zhai L., Zhang S., Zhou J., Wang J. Effects of Metabolic Syndrome and Its Components on the Prognosis of Endometrial Cancer. Front Endocrinol (Lausanne). 2021; 12. https://doi.org/10.3389/fendo.2021.780769.
  • Buono G., Crispo A., Giuliano M., De Angelis C., Schettini F., Forestieri V., Lauria R., De Laurentiis M., De Placido P., Rea C.G., Pacilio C., Esposito E., Grimaldi M., Nocerino F., Porciello G., Giudice A., Amore A., Minopoli A., Botti G., De Placido S., Trivedi M.V., Arpino G. Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat. 2020; 182(2):401-9. https://doi.org/10.1007/s10549-020-05701-7.
  • Li Y., Zhao J., Wu X., Zhang Y., Jin Y., Cai W. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer. Aging (Albany NY). 2021; 13(4): 5442-60. https://doi.org/10.18632/aging.202474.
  • Bhome R., Peppa N., Karar S., McDonnell D., Mirnezami A., Hamady Z. Metabolic syndrome is a predictor of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study of 1006 patients. Eur J Surg Oncol. 2021; 47(7): 1623-8. https://doi.org/10.1016/j.ejso.2020.12.016.
  • Han F., Wu G., Zhang S., Zhang J., Zhao Y., Xu J. The association of metabolic syndrome and its components with the incidence and survival of colorectal cancer: a systematic review and meta-analysis. Int J Biol Sci. 2021; 17(2): 487-97. https://doi.org/10.7150/ijbs.52452.
  • Zhou J., Massey S., Story D., Li L. Metformin: An Old Drug with New Applications. Int J Mol Sci. 2018; 19(10): 2863. https://doi.org/10.3390/ijms19102863.
  • Fahed G., Aoun L., Bou Zerdan M., Allam S., Bou Zerdan M., Bouferraa Y., Assi H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2): 786. https://doi.org/10.3390/ijms23020786.
  • Gluvic Z., Zaric B., Resanovic I., Obradovic M., Mitrovic A., Radak D., Isenovic E.R. Link between Metabolic Syndrome and Insulin Resistance. Curr Vasc Pharmacol. 2017; 15(1): 30-9. https://doi.org/10.2174/1570161114666161007164510.
  • McCracken E., Monaghan M., Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018; 36(1): 14-20. https://doi.org/10.1016/j.clindermatol.2017.09.004.
  • Battelli M.G., Bortolotti M., Polito L., Bolognesi A. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase. Redox Biol. 2019; 21. https://doi.org/10.1016/j.redox.2018.101070.
  • Ivanov V.V., Shakhristova E.V., Stepovaya E.A., Nosareva O.L., Fedorova T.S., Ryazantseva N.V., Novitskii V.V. Okislitel'nyi stress: vliyanie na sekretsiyu insulina, retseptsiyu gormona adipotsitami i lipoliz v zhirovoi tkani. Byulleten' sibirskoi meditsiny. 2014;13(3): 32-9. https://doi.org/10.20538/1682-0363-2014-3-32-39.
  • Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Chernyshova A.L., Kudryavtsev I.V., Tsydenova A.A. Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors). Asia Pac J Clin Oncol. 2018; 14(3): 134-40. https://doi.org/10.1111/ajco.12780.
  • Zhang A.M.Y., Wellberg E.A., Kopp J.L., Johnson J.D. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J. 2021;45(3): 285-311. https://doi.org/10.4093/dmj.2020.0250.
  • Chen M., Linstra R., van Vugt M.A.T.M. Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2022; 1877(1). https://doi.org/10.1016/j.bbcan.2021.188661.
  • Di Zazzo E., Polito R., Bartollino S., Nigro E., Porcile C., Bianco A., Daniele A., Moncharmont B. Adiponectin as Link Factor between Adipose Tissue and Cancer. Int J Mol Sci. 2019; 20(4): 839. https://doi.org/10.3390/ijms20040839.
  • Garikapati K.K., Ammu V.V.V.R.K., Krishnamurthy P.T., Chintamaneni P.K., Pindiprolu S.K.S.S. Type-II endometrial cancer: role of adipokines. Arch Gynecol Obstet. 2019; 300(2): 239-49. https://doi.org/10.1007/s00404-019-05181-1.
  • Kahn C.R., Wang G., Lee K.Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129(10): 3990-4000. https://doi.org/10.1172/JCI129187.
  • Słabuszewska-Jóźwiak A., Lukaszuk A., Janicka-Kośnik M., Wdowiak A., Jakiel G. Role of Leptin and Adiponectin in Endometrial Cancer. Int J Mol Sci. 2022; 23(10): 5307. https://doi.org/10.3390/ijms23105307.
  • Daley-Brown D., Oprea-Ilies G.M., Lee R., Pattillo R., Gonzalez- Perez R.R. Molecular cues on obesity signals, tumor markers and endometrial cancer. Horm Mol Biol Clin Investig. 2015; 21(1): 89-106. https://doi.org/10.1515/hmbci-2014-0049.
  • Vavilova T.P., Pleten’A.P., Mikheev R.K. [Biological role of adipokines and their association with morbid conditions]. Vopr Pitan. 2017;86(2): 5-13. Russian. https://doi.org/10.24411/0042-8833-2017-00028.
  • Socol C.T., Chira A., Martinez-Sanchez M.A., Nuñez-Sanchez M.A., Maerescu C.M., Mierlita D., Rusu A.V., Ruiz-Alcaraz A.J., Trif M., Ramos-Molina B. Leptin Signaling in Obesity and Colorectal Cancer. Int J Mol Sci. 2022; 23(9): 4713. https://doi.org/10.3390/ijms23094713.
  • Ilhan T.T., Kebapcilar A., Yilmaz S.A., Ilhan T., Kerimoglu O.S., Pekin A.T., Akyurek F., Unlu A., Celik C. Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis. Asian Pac J Cancer Prev. 2015; 16(11): 4503-8. https://doi.org/10.7314/apjcp.2015.16.11.4503.
  • Stępień S., Olczyk P., Gola J., Komosińska-Vassev K., Mielczarek-Palacz A. The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer. Cells. 2023; 12(8): 1118. https://doi.org/10.3390/cells12081118.
  • Michalczyk K., Niklas N., Rychlicka M., Cymbaluk-Płoska A. The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. Diagnostics (Basel). 2021; 11(3): 494. https://doi.org/10.3390/diagnostics11030494.
  • VriensK.,ChristenS.,ParikS.,BroekaertD.,YoshinagaK.,TalebiA., Dehairs J., Escalona-Noguero C., Schmieder R., Cornfield T., Charlton C., Romero-Pérez L., Rossi M., Rinaldi G., Orth M.F., Boon R., Kerstens A., Kwan S.Y., Faubert B., Méndez-Lucas A., Kopitz C.C., Chen T., Fernandez-Garcia J., Duarte J.A.G., Schmitz A.A., Steigemann P., Najimi M., Hägebarth A., van Ginderachter J.A., Sokal E., Gotoh N., Wong K.K., Verfaillie C., Derua R., Munck S., Yuneva M., Beretta L., DeBerardinis R.J., Swinnen J.V., Hodson L., Cassiman D., Verslype C., Christian S., Grünewald S., Grünewald T.G.P., Fendt S.M. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566(7744): 403-6. https://doi.org/10.1038/s41586-019-0904-1.
  • Kulikov V.A., Grebennikov I.N. Rezolviny, protektiny, mareziny: novye mediatory vospaleniya. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2012; 2: 25-30.
  • Panigrahy D., Gilligan M.M., Serhan C.N., Kashfi K. Resolution of inflammation:An organizing principle in biology and medicine. Pharmacol Ther. 2021; 227. https://doi.org/10.1016/j.pharmthera.2021.107879.
  • Tang S., Wan M., Huang W., Stanton R.C., Xu Y. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. Mediators Inflamm. 2018. https://doi.org/10.1155/2018/2380319.
  • Kelly A.G., Panigrahy D. TargetingAngiogenesis via Resolution of Inflammation. Cold Spring Harb Perspect Med. 2023; 13(3). https://doi.org/10.1101/cshperspect.a041172.
  • Liotti F., Marotta M., Melillo R.M., Prevete N. The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression. Cancers (Basel). 2022; 14(14): 3333. https://doi.org/10.3390/cancers14143333.
  • Dyall S.C., Balas L., Bazan N.G., Brenna J.T., Chiang N., da Costa Souza F., Dalli J., Durand T., Galano J.M., Lein P.J., Serhan C.N., Taha A.Y. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions. Prog Lipid Res. 2022; 86. https://doi.org/10.1016/j.plipres.2022.101165.
  • Doğan E.S.K., Doğan B., Fentoğlu Ö., Kırzıoğlu F.Y. The role of serum lipoxin A4 levels in the association between periodontal disease and metabolic syndrome. J Periodontal Implant Sci. 2019; 49(2): 105-13. https://doi.org/10.5051/jpis.2019.49.2.105.
  • Denisenko Y.K., Kytikova O.Y., Novgorodtseva T.P., Antonyuk M.V., Gvozdenko T.A., Kantur T.A. Lipid-Induced Mechanisms of Metabolic Syndrome. J Obes. 2020. https://doi.org/10.1155/2020/5762395.
  • Börgeson E., Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol. 2012; 3: 318. https://doi.org/10.3389/fimmu.2012.00318.
  • Kolawole O.R., Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci. 2022; 23(3): 1432. https://doi.org/10.3390/ijms23031432.
  • Serhan C.N., Levy B.D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018; 128(7):2657-69. https://doi.org/10.1172/JCI97943.
  • Shan K., Feng N., Cui J., Wang S., Qu H., Fu G., Li J., Chen H., Wang X., Wang R., Qi Y., Gu Z., Chen Y.Q. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med. 2020; 24(14): 8045-56. https://doi.org/10.1111/jcmm.15436.
  • Ji R.R. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. Ann Rev Pharmacol Toxicol. 2023; 63: 273-93. https://doi.org/10.1146/annurev-pharmtox-051921-084047.
  • Martínez-Fernández L., Laiglesia L.M., Huerta A.E., Martínez J.A., Moreno-Aliaga M.J. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostaglandins Other Lipid Mediat. 2015;121(Pt A): 24-41. https://doi.org/10.1016/j.prostaglandins.2015.07.003.
  • Serhan C.N., Sulciner M.L. Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic? Cancer Metastasis Rev. 2023; 42(1): 13-7. https://doi.org/10.1007/s10555-023-10091-5.
  • Harwood J.L. Polyunsaturated Fatty Acids: Conversion to Lipid Mediators, Roles in Inflammatory Diseases and Dietary Sources. Int J Mol Sci. 2023; 24(10). https://doi.org/10.3390/ijms24108838.
  • Al-Shaer A.E., Buddenbaum N., Shaikh S.R. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Biochim BiophysActa Mol Cell Biol Lipids. 2021; 1866(7). https://doi.org/10.1016/j.bbalip.2021.158936.
  • Polus A., Zapala B., Razny U., Gielicz A., Kiec-Wilk B., Malczewska-Malec M., Sanak M., Childs C.E., Calder P.C., Dembinska-Kiec A. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim Biophys Acta. 2016; 1861(11): 1746-55. https://doi.org/10.1016/j.bbalip.2016.08.005.
  • Dubé L., Spahis S., Lachaîne K., Lemieux A., Monhem H., Poulin S.M., Randoll C., Travaillaud E., Ould-Chikh N.E., Marcil V., Delvin E., Levy E. Specialized Pro-Resolving Mediators Derived from N-3 Polyunsaturated Fatty Acids: Role in Metabolic Syndrome and Related Complications. Antioxid Redox Signal. 2022; 37(1-3): 54-83. https://doi.org/10.1089/ars.2021.0156.
  • Sáinz N., Fernández-Galilea M., Costa AGV, Prieto-Hontoria P.L., Barraco G.M., Moreno-Aliaga M.J. n-3 polyunsaturated fatty acids regulate chemerin in cultured adipocytes: role of GPR120 and derived lipid mediators. Food Funct. 2020; 11(10): 9057-66. https://doi.org/10.1039/d0fo01445a.
  • Martínez-Fernández L., González-Muniesa P., Laiglesia L.M., Sáinz N., Prieto-Hontoria P.L., Escoté X., Odriozola L., Corrales F.J., Arbones-Mainar J.M., Martínez J.A., Moreno-Aliaga M.J. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J. 2017; 31(5): 2135-45. https://doi.org/10.1096/fj.201600859R.
  • Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas'ev S.G., Chernyshova A.L., Shatokhina O.V., Frolova A.E., Zhiwei Zh., Wei W. Adipokiny i ikh retseptory u bol'nykh rakom endometriya i obodochnoi kishki: svyaz' s invaziei i metastazirovaniem. Voprosy onkologii. 2015; 61(4): 619-23.
  • Barden A., Shinde S., Tsai I.J., Croft K.D., Beilin L.J., Puddey I.B., Mori T.A. Effect of weight loss on neutrophil resolvins in the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2019; 148: 25-9. https://doi.org/10.1016/j.plefa.2019.07.001.
  • Liu H., Zeng J., Huang W., Xu Q., Ye D., Sun R., Zhang D. Colorectal Cancer Is Associated with a Deficiency of Lipoxin A , an Endogenous Anti-inflammatory Mediator. J Cancer. 2019; 10(19): 4719-30. https://doi.org/10.7150/jca.32456.
  • Blogowski W., Dolegowska K., Deskur A., Dolegowska B., Starzynska T. Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report. Front Oncol. 2022; 11. https://doi.org/10.3389/fonc.2021.757073.
  • Torres W., Pérez J.L., Díaz M.P., D’Marco L., Checa-Ros A., Carrasquero R., Angarita L., Gómez Y., Chacín M., Ramírez P., Villasmil N., Durán-Agüero S., Cano C., Bermúdez V. The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis. Int J Mol Sci. 2023; 24(16). https://doi.org/10.3390/ijms241612623.
  • Al-Zaubai N., Johnstone C.N., Leong M.M., Li J., Rizzacasa M., Stewart A.G. Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor. J Pharmacol Exp Ther. 2014; 351(1): 172-80. https://doi.org/10.1124/jpet.114.214403.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp